574 related articles for article (PubMed ID: 14750899)
1. The health economics of bladder cancer: a comprehensive review of the published literature.
Botteman MF; Pashos CL; Redaelli A; Laskin B; Hauser R
Pharmacoeconomics; 2003; 21(18):1315-30. PubMed ID: 14750899
[TBL] [Abstract][Full Text] [Related]
2. The health economics of bladder cancer: an updated review of the published literature.
Yeung C; Dinh T; Lee J
Pharmacoeconomics; 2014 Nov; 32(11):1093-104. PubMed ID: 25056838
[TBL] [Abstract][Full Text] [Related]
3. The economics of bladder cancer: costs and considerations of caring for this disease.
Svatek RS; Hollenbeck BK; Holmäng S; Lee R; Kim SP; Stenzl A; Lotan Y
Eur Urol; 2014 Aug; 66(2):253-62. PubMed ID: 24472711
[TBL] [Abstract][Full Text] [Related]
4. Contemporary cost-effectiveness analysis comparing sequential bacillus Calmette-Guerin and electromotive mitomycin versus bacillus Calmette-Guerin alone for patients with high-risk non-muscle-invasive bladder cancer.
Bachir BG; Dragomir A; Aprikian AG; Tanguay S; Fairey A; Kulkarni GS; Breau RH; Black PC; Kassouf W
Cancer; 2014 Aug; 120(16):2424-31. PubMed ID: 24752448
[TBL] [Abstract][Full Text] [Related]
5. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
6. Economic impact of tumor markers in bladder cancer surveillance.
Hong YM; Loughlin KR
Urology; 2008 Jan; 71(1):131-5. PubMed ID: 18242381
[TBL] [Abstract][Full Text] [Related]
7. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
[TBL] [Abstract][Full Text] [Related]
8. Healthcare economics of bladder cancer: cost-enhancing and cost-reducing factors.
Noyes K; Singer EA; Messing EM
Curr Opin Urol; 2008 Sep; 18(5):533-9. PubMed ID: 18670280
[TBL] [Abstract][Full Text] [Related]
9. [Urine cytology and new markers. Are there any advantages in terms of cost-effectiveness?].
Campodonico F
Urologia; 2013; 80 Suppl 21():7-10. PubMed ID: 23559136
[TBL] [Abstract][Full Text] [Related]
10. The burden of bladder cancer care: direct and indirect costs.
Mossanen M; Gore JL
Curr Opin Urol; 2014 Sep; 24(5):487-91. PubMed ID: 24887047
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer.
Kulkarni GS; Alibhai SM; Finelli A; Fleshner NE; Jewett MA; Lopushinsky SR; Bayoumi AM
Cancer; 2009 Dec; 115(23):5450-9. PubMed ID: 19685529
[TBL] [Abstract][Full Text] [Related]
12. Economic Burden of Bladder Cancer Across the European Union.
Leal J; Luengo-Fernandez R; Sullivan R; Witjes JA
Eur Urol; 2016 Mar; 69(3):438-47. PubMed ID: 26508308
[TBL] [Abstract][Full Text] [Related]
13. Economic aspects of bladder cancer: what are the benefits and costs?
Sievert KD; Amend B; Nagele U; Schilling D; Bedke J; Horstmann M; Hennenlotter J; Kruck S; Stenzl A
World J Urol; 2009 Jun; 27(3):295-300. PubMed ID: 19271220
[TBL] [Abstract][Full Text] [Related]
14. Cost-effective treatment of low-risk carcinoma not invading bladder muscle.
Green DA; Rink M; Cha EK; Xylinas E; Chughtai B; Scherr DS; Shariat SF; Lee RK
BJU Int; 2013 Mar; 111(3 Pt B):E78-84. PubMed ID: 22958598
[TBL] [Abstract][Full Text] [Related]
15. Surgical advances in bladder cancer: at what cost?
Johnson DC; Greene PS; Nielsen ME
Urol Clin North Am; 2015 May; 42(2):235-52, ix. PubMed ID: 25882565
[TBL] [Abstract][Full Text] [Related]
16. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.
Uchida A; Yonou H; Hayashi E; Iha K; Oda M; Miyazato M; Oshiro Y; Hokama S; Sugaya K; Ogawa Y
Urology; 2007 Feb; 69(2):275-9. PubMed ID: 17320663
[TBL] [Abstract][Full Text] [Related]
17. [Cost-effectiveness of transurethral resection of the bladder with blue light in patients with non muscle invasive bladder cancer in France].
Rouprêt M; Malavaud B; Molinier L; Leleu H; Blachier M; Marteau F
Prog Urol; 2015 Apr; 25(5):256-64. PubMed ID: 25605343
[TBL] [Abstract][Full Text] [Related]
18. The costs of non-muscle invasive bladder cancer.
James AC; Gore JL
Urol Clin North Am; 2013 May; 40(2):261-9. PubMed ID: 23540783
[TBL] [Abstract][Full Text] [Related]
19. The cost of bladder tumour treatment and follow-up.
Hedelin H; Holmäng S; Wiman L
Scand J Urol Nephrol; 2002; 36(5):344-7. PubMed ID: 12487738
[TBL] [Abstract][Full Text] [Related]
20. Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis.
Lotan Y; Svatek RS; Sagalowsky AI
Cancer; 2006 Sep; 107(5):982-90. PubMed ID: 16862567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]